A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Langley, Joanne M ^a   Frenette, Louise ^b   Chu, Laurence ^c   McNeil, Shelly ^a   Halperin, Scott ^a   Li, Ping ^d   Vaughn, David ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QandT Research Inc   (Canada)

^c Benchmark Research   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; AS03; Co administration; H1N1; Influenza; Pandemic; TIV

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PLACEBO;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COUGHING; DRUG INDUCED HEADACHE; DRUG SAFETY; FACIAL NERVE PARALYSIS; FATIGUE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INJECTION SITE PAIN; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEASONAL INFLUENZA; SEROCONVERSION; SIDE EFFECT; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; DRUG COMBINATIONS; DRUG TOXICITY; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84867899922     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-279     Document Type: Article

References (15)

1. Chowell G, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009, 361(7):674-679. 10.1056/NEJMoa0904023, 19564633.
2. Centers for Disease Control and Prevention Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - April 10, 2010 2010, Morbidity and Mortality Weekly Report, (Published by CDC Atlanta), Centers for Disease Control and Prevention.
3. National Institute of Allergy and Infectious Diseases Bulletin: Early results: NIAID trial supports co-administration of 2009 H1N1 influenza vaccine and seasonal influenza vaccine 2009, [cited 2009 October 9, 2009.]; Available from: http://www.niaid.nih.gov/news/newsreleases/2009/pages/h1n1plusseasonalvax.aspx, National Institute of Allergy and Infectious Diseases.
4. Strategic Advisory Group of Experts. Global Alert and Response WHO recommendations on pandemic (H1N1) 2009 vaccines 2009, [cited 2009 10 October 2009]; Available from: WHO recommendations on pandemic (H1N1) 2009 vaccines, Strategic Advisory Group of Experts. Global Alert and Response.
5. Peeters S, et al. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials. Vaccine 2012, 30:6483-6491. 10.1016/j.vaccine.2012.07.081, 22885014.
6. Vajo Z, et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375(9708):49-55. 10.1016/S0140-6736(09)62039-0, 20018367.
7. Gasparini R, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010, 64(4):432-438. 10.1111/j.1742-1241.2009.02309.x, 20039974.
8. Global Advisory and Safety Committee World Health Oragnization Thiomersal and vaccines: questions and answers 2006, [cited 2011 Oct 3]; Available from: http://www.who.int/vaccine_safety/topics/thiomersal/questions/en/index.html, Global Advisory and Safety Committee World Health Oragnization.
9. Lee VJ, et al. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 2010, 28(42):6852-6857. 10.1016/j.vaccine.2010.08.031, 20723626.
10. Xie H, et al. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 2011, 6(1):e16650. 10.1371/journal.pone.0016650, 3031605, 21304946.
11. Manzoli L, et al. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 2011, 6(9):e24384. 10.1371/journal.pone.0024384, 3167852, 21915319.
12. Roman F, et al. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51(6):668-677. 10.1086/655830, 20687838.
13. Hehme NW, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix(TM). Clin Drug Invest 2002, 22:751-769.
14. European Committee for Proprietary Medicinal Products (CHMP) European Agency for the Evaluation of Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006) 2007, 11. London: European Medicines Agency, European Committee for Proprietary Medicinal Products (CHMP).
15. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. FDA 2007, Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/quidances/vaccines/ucm091990.pdf, U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research.